GRAIL Submits FDA Premarket Approval for Galleri Multi-Cancer Detection Test
Event summary
- GRAIL submitted the final module of its Premarket Approval (PMA) application to the FDA for the Galleri multi-cancer early detection test on January 29, 2026.
- The submission includes data from 25,490 participants in the PATHFINDER 2 study and the NHS-Galleri trial, the largest randomized controlled trial of any MCED test.
- The Galleri test aims to detect multiple cancer types early, addressing the unmet need in current cancer screening programs.
- The FDA designated the test as a Breakthrough Device in 2018.
The big picture
GRAIL's submission marks a critical step in advancing early cancer detection, addressing the high mortality rates due to late-stage cancer diagnoses. The Galleri test, if approved, could transform cancer screening by detecting multiple cancer types early, potentially improving treatment outcomes and reducing healthcare costs. The strategic significance lies in the test's ability to complement existing screening programs, offering a more comprehensive approach to early detection.
What we're watching
- Regulatory Approval
- The pace at which the FDA reviews and approves the Galleri test will determine its commercial availability and impact on cancer screening.
- Clinical Efficacy
- Whether the Galleri test can demonstrate a significant reduction in late-stage cancer diagnoses compared to standard screening methods.
- Market Adoption
- How healthcare systems and insurers will integrate the Galleri test into existing cancer screening protocols and reimbursement models.
Related topics